论文部分内容阅读
目的:探讨吉西他滨联合奥沙利铂方案对复发或转移的胸腺癌患者近期临床疗效。方法:采用吉西他滨1 000 mg·m-2,分别d1、d8静脉点滴,30~60 min滴完;奥沙利铂130 mg·m-2,d2静脉泵入,2 h滴完,21 d为1个周期。化疗至少2个周期。结果:42例患者者临床有效率为42.9%,疾病控制率为73.9%,其中胸腺鳞癌有效率高达62.5%。不良反应以骨髓抑制及外周神经毒性常见,但大多可以耐受。结论:吉西他滨联合奥沙利铂对复发转移胸腺癌具有一定临床疗效,鳞癌患者似乎获益更多。
Objective: To investigate the short-term clinical efficacy of gemcitabine combined with oxaliplatin in patients with recurrent or metastatic thymoma. Methods: Gemcitabine was administered intravenously at 1 000 mg · m-2 at d1 and d8 for 30-60 min. Oxaliplatin was infused intravenously at 130 mg · m-2 and d2 for 2 h. 1 cycle. Chemotherapy at least 2 cycles. Results: The clinical effective rate was 42.9% in 42 patients, the disease control rate was 73.9%, and the effective rate of thymic carcinoma was 62.5%. Adverse reactions to myelosuppression and peripheral neurotoxicity are common, but most can be tolerated. Conclusion: Gemcitabine combined with oxaliplatin has a certain clinical effect on recurrent and metastatic thymic carcinoma, and patients with squamous cell carcinoma seem to benefit more.